Cardiac Failure Review最新文献_第10页

High-flow Nasal Cannula Oxygenation Revisited in COVID-19. 高流量鼻插管氧合在COVID-19中的应用

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.06

Aniket S Rali, Krishidhar R Nunna, Christopher Howard, James P Herlihy, Kalpalatha K Guntupalli

引用次数: 5

Telemonitoring for the Management of Patients with Heart Failure. 心衰患者的远程监护管理。

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.20

Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani

{"title":"Telemonitoring for the Management of Patients with Heart Failure.","authors":"Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani","doi":"10.15420/cfr.2019.20","DOIUrl":"https://doi.org/10.15420/cfr.2019.20","url":null,"abstract":"Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/ae/cfr-06-e07.PMC7199126.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37909594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Telemonitoring in Heart Failure Management. 心衰管理中的远程监护。

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.12

Ivo Planinc, Davor Milicic, Maja Cikes

引用次数: 14

Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure. 肺静脉隔离与胺碘酮治疗并发持续性房颤和充血性心力衰竭患者的长期疗效比较。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.03

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty, Chintan Trivedi, Ugur Canpolat, Carola Gianni, Amin Al-Ahmad, Rodney Horton, Gerald Joseph Gallinghouse, John David Burkhardt, Andrea Natale

引用次数: 0

The Use of App-based Follow-up of Cardiac Implantable Electronic Devices. 心脏植入式电子装置app随访的应用。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.13

Paul Richard Roberts, Mohamed Hassan ElRefai

引用次数: 10

Pulmonary Hypertension in Heart Failure Patients. 心力衰竭患者的肺动脉高压。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.09

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek

引用次数: 12

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. 保留射血分数对心力衰竭致瘤性2的抑制作用。

Cardiac Failure Review Pub Date : 2020-03-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.10

Veronika Zach, Felix Lucas Bähr, Frank Edelmann

{"title":"Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction.","authors":"Veronika Zach, Felix Lucas Bähr, Frank Edelmann","doi":"10.15420/cfr.2019.10","DOIUrl":"https://doi.org/10.15420/cfr.2019.10","url":null,"abstract":"Heart failure (HF), with steadily increasing incidence rates and mortality in an ageing population, represents a major challenge. Evidence suggests that more than half of all patients with a diagnosis of HF suffer from HF with preserved ejection fraction (HFpEF). Emerging novel biomarkers to improve and potentially guide the treatment of HFpEF are the subject of discussion. One of these biomarkers is suppression of tumourigenicity 2 (ST2), a member of the interleukin (IL)-1 receptor family, binding to IL-33. Its two main isoforms - soluble ST2 (sST2) and transmembrane ST2 (ST2L) - show opposite effects in cardiovascular diseases. While the ST2L/IL-33 interaction is considered as being cardioprotective, sST2 antagonises this beneficial effect by competing for binding to IL-33. Recent studies show that elevated levels of sST2 are associated with increased mortality in HF with reduced ejection fraction. Nevertheless, the significance of sST2 in HFpEF remains uncertain. This article aims to give an overview of the current evidence on sST2 in HFpEF with an emphasis on prognostic value, clinical association and interaction with HF treatment. The authors conclude that sST2 is a promising biomarker in HFpEF. However, further research is needed to fully understand underlying mechanisms and ultimately assess its full value.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/e6/cfr-06-e02.PMC7111301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Temporary Mechanical Circulatory Support in Acute Heart Failure. 急性心力衰竭的临时机械循环支持。

IF 4.2

Cardiac Failure Review Pub Date : 2020-03-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.02

Federica Jiritano, Valeria Lo Coco, Matteo Matteucci, Dario Fina, Anne Willers, Roberto Lorusso

{"title":"Temporary Mechanical Circulatory Support in Acute Heart Failure.","authors":"Federica Jiritano, Valeria Lo Coco, Matteo Matteucci, Dario Fina, Anne Willers, Roberto Lorusso","doi":"10.15420/cfr.2019.02","DOIUrl":"10.15420/cfr.2019.02","url":null,"abstract":"Cardiogenic shock (CS) is a challenging syndrome, associated with significant morbidity and mortality. Although pharmacological therapies are successful and can successfully control this acute cardiac illness, some patients remain refractory to drugs. Therefore, a more aggressive treatment strategy is needed. Temporary mechanical circulatory support (TCS) can be used to stabilise patients with decompensated heart failure. In the last two decades, the increased use of TCS has led to several kinds of devices becoming available. However, indications for TCS and device selection are part of a complex process. It is necessary to evaluate the severity of CS, any early and prompt haemodynamic resuscitation, prior TCS, specific patient risk factors, technical limitations and adequacy of resources and training, as well as an assessment of whether care would be futile. This article examines options for commonly used TCS devices, including intra-aortic balloon pumps, a pulsatile percutaneous ventricular assist device (the iVAC), veno-arterial extra-corporeal membrane oxygenation and Impella (Abiomed) and TandemHeart (LivaNova) percutaneous ventricular assist device.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e01"},"PeriodicalIF":4.2,"publicationDate":"2020-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/ce/cfr-06-e01.PMC7111303.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37810000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice 肌力药物治疗急性心力衰竭:从指南到实际应用:治疗选择和临床实践

Cardiac Failure Review Pub Date : 2019-11-01 DOI: 10.15420/cfr.2019.11.2

V. Bistola, A. Arfaras-Melainis, Eftihia V Polyzogopoulou, I. Ikonomidis, J. Parissis

{"title":"Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice","authors":"V. Bistola, A. Arfaras-Melainis, Eftihia V Polyzogopoulou, I. Ikonomidis, J. Parissis","doi":"10.15420/cfr.2019.11.2","DOIUrl":"https://doi.org/10.15420/cfr.2019.11.2","url":null,"abstract":"Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"5 1","pages":"133 - 139"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46511535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 29

Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment 右心室衰竭:病理生理学、诊断和治疗

Cardiac Failure Review Pub Date : 2019-11-01 DOI: 10.15420/cfr.2019.15.2

M. Arrigo, L. Huber, S. Winnik, F. Mikulicic, F. Guidetti, M. Frank, A. Flammer, F. Ruschitzka

引用次数: 68